-
1.发明公开ＤＮＡ 표적 약품 결합 ＤＮＡ의 탄성을 측정하는 방법 및 이를 이용한 ＤＮＡ의 ＤＮＡ 표적 약품의 결합정도를 측정하는 방법 无效DNA靶向药物结合DNA的弹性的估计方法和使用该方法的DNA结合度估计方法
公开(公告)号：KR1020100062336A
公开(公告)日：2010-06-10
申请号：KR1020080120932
申请日：2008-12-02
Applicant: 서울대학교산학협력단
Abstract: PURPOSE: A method for measuring elasticity of DNA targeting drug-bound DNA and a method for measuring binding degree of DNA and DNA targeting drug are provided to find physical property of DNA. CONSTITUTION: A method for measuring elasticity of DNA targeting drug-bound DNA is performed by measuring tension and length to a binding DNA. A method for measuring relation of tension and length is defined by WLC having changing continuous length by formula 3 in force-length curve of WLC model of formula 1 in case of lack of interelation between kinks generated by binding. The binding with DNA targeting drug is performed in a proper tension and salt concentration.
Abstract translation: 目的：提供一种测定靶向药物结合DNA的DNA弹性的方法以及测定DNA和DNA靶向药物结合程度的方法，以找出DNA的物理性质。 构成：通过测量结合DNA的张力和长度来测量靶向药物结合的DNA的DNA的弹性的方法。 用于测量张力和长度关系的方法由WLC定义，WLC在结合产生的扭结之间缺乏相互作用的情况下，通过公式3的WLC模型的力 - 长度曲线中具有连续长度改变的连续长度。 与DNA靶向药物的结合以适当的张力和盐浓度进行。
-
公开(公告)号：KR1020140019261A
公开(公告)日：2014-02-14
申请号：KR1020130159707
申请日：2013-12-19
Applicant: 서울대학교산학협력단
Abstract: The present invention relates to tumor stem cell targeting peptide GICT which can selectively recognize and bind malignant undifferentiated brain tumor stem cells, and a diagnosis method of brain tumor using the peptide. The present invention provides a pharmaceutical composition for preventing and treating malignant tumor which contains the tumor stem cell targeting peptide denoted by sequence number 1 as an effective component.
Abstract translation: 本发明涉及可以选择性识别和结合恶性未分化脑肿瘤干细胞的肿瘤干细胞靶向肽GICT，以及使用该肽的脑肿瘤诊断方法。 本发明提供了含有以序列号1表示的肿瘤干细胞靶向肽作为有效成分的恶性肿瘤的预防和治疗药物组合物。
-
Patent Agency Ranking
-
公开(公告)号：KR1020120099904A
公开(公告)日：2012-09-12
申请号：KR1020110018414
申请日：2011-03-02
Applicant: 서울대학교산학협력단
CPC classification number: C07K7/06 , A61K38/08 , A61K47/66 , G01N33/57407
Abstract: PURPOSE: A malignant undifferentiated cancer stem cell target peptide is provided to effectively and accurately deliver anti-cancer drug to tumor cells by targeting nestin-positive cells of tumor cells. CONSTITUTION: A malignant undifferentiated cancer stem cell target peptide GICT has AQYLNPS sequence which can selectively recognizes and combines with the malignant undifferentiated tumor stem cells. A marker for diagnosing malignant cancers uses the cancer stem cell target peptide GICT having AQYLNPS sequence. A method for screening the cancer stem cell target peptide, which can selectively recognize and combine with the malignant undifferentiated cancer stem cells, uses phage display technique. The method for sorting and inspecting the cancer stem cell target peptide comprises the following steps: prying the cancer stem cell target peptides through sorting the cancer stem cell bonded phage and analyzing the individual phage combination aspect by using the page display technique; analyzing combining ability of the pried cancer stem cell target peptide with the various cells; sorting and verifying the protein bonded with the pried cancer stem cell target peptide; verifying the cancer tissue transmission ability of the cancer stem cell target peptide in a cancer model mouse; verifying undifferentiated cancer stem cell specific targeting ability of the cancer stem cell target peptide in the brain tumor organization; and confirming the cancer cell growth inhibition ability in the tumor model mouse of the tumor stem cell target peptide.
Abstract translation: 目的：通过靶向肿瘤细胞的巢蛋白阳性细胞，提供恶性未分化癌症干细胞靶肽，以有效和准确地将抗癌药物递送至肿瘤细胞。 构成：恶性未分化癌症干细胞靶肽GICT具有AQYLNPS序列，可以选择性识别和与恶性未分化肿瘤干细胞结合。 用于诊断恶性肿瘤的标记物使用具有AQYLNPS序列的癌干细胞靶肽GICT。 筛选可以选择性识别和与恶性未分化癌细胞结合的癌干细胞靶肽的方法，使用噬菌体展示技术。 癌症干细胞靶肽分选检测方法包括以下步骤：通过分选癌干细胞粘附的噬菌体，通过使用页面显示技术分析单个噬菌体组合方面，来窥探癌症干细胞靶肽; 分析pri癌干细胞靶肽与各种细胞的结合能力; 分选和验证与脯氨酸癌干细胞靶肽结合的蛋白质; 验证癌症模型小鼠中癌干细胞靶肽的癌组织传播能力; 验证癌症干细胞靶肽在脑肿瘤组织中的未分化癌干细胞特异性靶向能力; 并确认肿瘤干细胞靶肽的肿瘤模型小鼠中的癌细胞生长抑制能力。
-
公开(公告)号：KR101327555B1
公开(公告)日：2013-11-08
申请号：KR1020110022096
申请日：2011-03-11
Applicant: 서울대학교산학협력단
CPC classification number: Y02A50/473
Abstract: 본 발명은 모공을 통해 피부를 투과하는 경피전달용 펩타이드에 관한 것으로, 본 발명에 의해 동정된 모공 투과 경피전달용 펩타이드 리간드는 경피 경로를 통한 거대 약물 분자의 체내 전달을 촉진시키는데 유용하게 이용될 수 있다.
-
公开(公告)号：KR1020120104036A
公开(公告)日：2012-09-20
申请号：KR1020110022096
申请日：2011-03-11
Applicant: 서울대학교산학협력단
CPC classification number: Y02A50/473 , C07K7/06 , A61K47/62
Abstract: PURPOSE: A transdermal peptide is provided to promote body delivery of large drug molecules. CONSTITUTION: A pore penetration peptide is SSHTISF, FPQPPQR, AFTPAKT or SPWIPAV. The transdermal peptide is SSHTISF, FPQPPQR, AFTPAKT or SPWIPAV. The SSHTISF peptide is ST1 peptide(Ser-Ser-His-Thr-Ile-Ser-Phe). The FPQPPQR peptide is ST2 peptide(Phe-Pro-Gln-Pro-Pro-Gln-Arg). The AFTPAKT peptide is ST2 peptide(Ala-Phe-Thr-Pro-Ala-Lys- Thr). The SPWIPAV peptide is ST4 peptide(Ser-Pro-Trp-Ile-Pro-Ala-Val). [Reference numerals] (AA) Repeat of biopanning round(1-3 times); (BB) Random transdermal administration of phage-peptide library into rat; (CC) Blood collection through heart at predetermined time after administration to collect skin penetrating phage; (DD) Amplificatioin of phage mixture collected from E.coli ER2738; (EE) Selecting each recombinant phage from biopanning of third round and determining peptide-coding nucleotide sequence; (FF) Peptide sequence identification from nucleotide sequence
Abstract translation: 目的：提供透皮肽以促进大量药物分子的体内递送。 构成：孔渗透肽是SSHTISF，FPQPPQR，AFTPAKT或SPWIPAV。 透皮肽是SSHTISF，FPQPPQR，AFTPAKT或SPWIPAV。 SSHTISF肽是ST1肽（Ser-Ser-His-Thr-Ile-Ser-Phe）。 FPQPPQR肽是ST2肽（Phe-Pro-Gln-Pro-Pro-Gln-Arg）。 AFTPAKT肽是ST2肽（Ala-Phe-Thr-Pro-Ala-Lys-Thr）。 SPWIPAV肽是ST4肽（Ser-Pro-Trp-Ile-Pro-Ala-Val）。 （附图标记）（AA）生物平扫重复（1-3次）; （BB）将噬菌体肽文库随机透皮给药至大鼠; （CC）在给药后的预定时间通过心脏采集皮肤渗透性噬菌体; （DD）从大肠杆菌ER2738收集的噬菌体混合物的扩增; （EE）从第三轮的生物淘选中选择每个重组噬菌体并确定肽编码的核苷酸序列; （FF）核苷酸序列的肽序列鉴定
-
-
-
-
-
-
Search Results
7
records
(took 0.023 seconds)
